# Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)

> **NCT01230177** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 3 (actual)

## Conditions studied

- Arthritis
- Rheumatoid

## Interventions

- **DRUG:** etanercept (genetical recombination)

## Key facts

- **NCT ID:** NCT01230177
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01230177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01230177, "Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01230177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*